VEDOLIZUMAB FOR THE PREVENTION OF IMMUNE CHECKPOINT INHIBITOR RELATED TO DIARREA OR COLITIS IN PATIENTS WITH CANCER. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL

Registry ID

VERIFY

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

ALBERTA HEALTH SERVICES

Start date

2026-08-13

Last update

2025-11-06

Conditions

• CANCER

Related clinical trials

• ProActIF-01 Trial: Feasibility Study of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Digestive Cancers
• TRIPTORELIN AND PROTECTION OF OVARIAN RESERVE IN ADOLESCENTS AND YOUNG ADULTS WITH CANCER
• OPTIMAL PRECISION THERAPIES TO CUSTOMISE CARE IN CHILDHOOD AND ADOLESCENT CANCER (OPTIMISE)
• AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOSULY ENROLLED IN A GENENTECH AND/OR F.HOFFMANLA ROCHE SPONSORED STUDY
• A PHASE 3, MULTICENTER, DOA PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF IVOSIDENIB IN PARTICIPANTS = 18 YEARS OF AGE WITH LOCALLY ADVANCED OR METASTATIC CONVENTIONAL CHONDROSARCOMA WITH AN IDH1 MUTATION, UNTREATED OR PREVIOUSLY
• PREVENTION OF THROMBOEMBOLISM WITH RIVAROXABAN IN GENITOURINARY CANCER PATIENTS RECEIVING SYSTEMIC THERAPY: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL

View on source registry